Miantenance olaparib for ovarian cancer – pro
On the basis of the results of SOLO1, maintenance therapy with olaparib is capped at 2 years in the first-line setting. For current disease, Gourley studies prolonged maintenance. At final DCO (May 9, 2016) median OS follow-up was 78.0 months.The Study 19 final analysis shows that olaparib provides clinically significant, long-term treatment benefit in pts with PSR SOC. A durable benefit was seen in >=10% of BRCAm and BRCAwt pts, who continued to receive and benefit from olaparib for >=6 years–unprecedented in the relapsed ovarian cancer setting. Similiar findings were obtained by DiSIlvestro et al.
NCCN Ovarian Cancer 2025
Paul DiSliverstro et al, Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. Journal of Clinical Oncology Volume 41, Number 3 , 2022
C. Gourley et al, Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)., 2017.